| Year |
Citation |
Score |
| 2020 |
Karim ME, Tremlett H, Zhu F, Petkau J, Kingwell E. Dealing with Treatment-confounder Feedback and Sparse Follow-up in Longitudinal studies - Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. American Journal of Epidemiology. PMID 33125039 DOI: 10.1093/aje/kwaa243 |
0.376 |
|
| 2019 |
Högg T, Zhao Y, Gustafson P, Petkau J, Fisk J, Marrie RA, Tremlett H. Adjusting for differential misclassification in matched case-control studies utilizing health administrative data. Statistics in Medicine. PMID 31115088 DOI: 10.1002/Sim.8203 |
0.354 |
|
| 2019 |
Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H. Multiple sclerosis: effect of beta interferon treatment on survival. Brain : a Journal of Neurology. PMID 30883636 DOI: 10.1093/Brain/Awz055 |
0.425 |
|
| 2017 |
Zhang T, Kingwell E, Zhu F, Petkau J, Kastrukoff LF, Marrie RA, Tremlett H, Evans C. Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. Bmj Open. 7: e018612. PMID 28965103 DOI: 10.1136/Bmjopen-2017-018612 |
0.373 |
|
| 2017 |
Högg T, Petkau J, Zhao Y, Gustafson P, Wijnands JM, Tremlett H. Bayesian analysis of pair-matched case-control studies subject to outcome misclassification. Statistics in Medicine. PMID 28783882 DOI: 10.1002/Sim.7427 |
0.321 |
|
| 2017 |
Kondo Y, Zhao Y, Petkau J. Identification of treatment responders based on multiple longitudinal outcomes with applications to multiple sclerosis patients. Statistics in Medicine. PMID 28147439 DOI: 10.1002/Sim.7230 |
0.383 |
|
| 2016 |
Karim ME, Petkau J, Gustafson P, Platt RW, Tremlett H. Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies. Statistical Methods in Medical Research. PMID 27659168 DOI: 10.1177/0962280216668554 |
0.318 |
|
| 2016 |
Karim ME, Gustafson P, Petkau J, Tremlett H. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. American Journal of Epidemiology. PMID 27455963 DOI: 10.1093/Aje/Kwv445 |
0.345 |
|
| 2016 |
Zhang T, Kingwell E, De Jong HJ, Zhu F, Zhao Y, Carruthers R, Petkau J, Gustafson P, Oger J, Tremlett H. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety. PMID 27211481 DOI: 10.1002/Pds.4031 |
0.407 |
|
| 2015 |
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, et al. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. PMID 26239222 DOI: 10.1007/S00415-015-7862-9 |
0.469 |
|
| 2015 |
Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment. Biomed Research International. 2015: 451912. PMID 25922836 DOI: 10.1155/2015/451912 |
0.404 |
|
| 2015 |
Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H. Beta-interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 990-1000. PMID 25846809 DOI: 10.1111/Ene.12698 |
0.461 |
|
| 2015 |
Kondo Y, Zhao Y, Petkau J. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients. Statistics in Medicine. 34: 2165-80. PMID 25784219 DOI: 10.1002/Sim.6484 |
0.412 |
|
| 2015 |
Reich DS, White R, Cortese IC, Vuolo L, Shea CD, Collins TL, Petkau J. Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25662351 DOI: 10.1177/1352458515569098 |
0.366 |
|
| 2015 |
Hartung HP, Kappos L, Goodin DS, O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, et al. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b Journal of Neurology. DOI: 10.1007/s00415-015-7862-9 |
0.317 |
|
| 2014 |
Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiology and Drug Safety. 23: 1213-22. PMID 24953054 DOI: 10.1002/Pds.3667 |
0.39 |
|
| 2014 |
Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. American Journal of Epidemiology. 180: 160-71. PMID 24939980 DOI: 10.1093/Aje/Kwu125 |
0.431 |
|
| 2014 |
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, ... ... Petkau J, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83: 278-86. PMID 24871874 DOI: 10.1212/Wnl.0000000000000560 |
0.442 |
|
| 2014 |
Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 21: 835-44. PMID 24351059 DOI: 10.1111/Ene.12324 |
0.411 |
|
| 2013 |
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Interferon beta and long-term disability in multiple sclerosis. Jama Neurology. 70: 651-2. PMID 23699948 DOI: 10.1001/Jamaneurol.2013.2197 |
0.351 |
|
| 2013 |
Riddell CA, Zhao Y, Petkau J. An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context. Statistical Methods in Medical Research. PMID 23592713 DOI: 10.1177/0962280213480576 |
0.453 |
|
| 2012 |
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Jama. 308: 247-56. PMID 22797642 DOI: 10.1001/Jama.2012.7625 |
0.448 |
|
| 2012 |
Tremlett H, Zhu F, Petkau J, Oger J, Zhao Y. Natural, innate improvements in multiple sclerosis disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1412-21. PMID 22736751 DOI: 10.1177/1352458512439119 |
0.428 |
|
| 2012 |
Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, Polman CH, Petkau J, Radue EW, Sormani MP, Li DK, O'Connor P, Montalban X, Miller DH, Filippi M. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews. Neurology. 8: 13-21. PMID 22143362 DOI: 10.1038/Nrneurol.2011.190 |
0.438 |
|
| 2012 |
Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 181-95. PMID 21952094 DOI: 10.1177/1352458511418629 |
0.369 |
|
| 2012 |
Hartung H, Kappos L, Goodin D, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, Bogumil T, Knappertz V, Beckmann K, Stemper B, Pohl C, et al. Predictors of Disease Activity in 857 MS Patients Treated with IFNB-1b (PD5.009) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pd5.009 |
0.333 |
|
| 2012 |
Shirani A, Petkau J, Tremlett H. Treatment with interferon beta for multiple sclerosis - Reply Jama - Journal of the American Medical Association. 308: 1627-1628. DOI: 10.1001/Jama.2012.13573 |
0.381 |
|
| 2011 |
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, et al. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 77: 835-43. PMID 21849647 DOI: 10.1212/Wnl.0B013E31822C90D7 |
0.437 |
|
| 2010 |
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. The Lancet. Neurology. 9: 740-50. PMID 20610349 DOI: 10.1016/S1474-4422(10)70103-4 |
0.44 |
|
| 2008 |
Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 770-8. PMID 18535021 DOI: 10.1177/1352458507088104 |
0.406 |
|
| 2008 |
Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, ... ... Petkau J, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 70: 1134-40. PMID 18362273 DOI: 10.1212/01.Wnl.0000306410.84794.4D |
0.402 |
|
| 2006 |
Li DKB, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability Neurology. 66: 1384-1389. PMID 16682671 DOI: 10.1212/01.Wnl.0000210506.00078.5C |
0.409 |
|
| 2005 |
Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li D, Menzler S, Miller DH, Petkau J, Wolinsky J. Predicting gadolinium, enhancement status in MS patients eligible for randomized clinical trials Neurology. 65: 1447-1454. PMID 16275834 DOI: 10.1212/01.Wnl.0000183149.87975.32 |
0.439 |
|
| 2004 |
Held U, Li D, Barkhof F, Petkau J. S13.1: Bayesian prediction of the number of lesions in multiple sclerosis trials Biometrical Journal. 46: 27-27. DOI: 10.1002/Bimj.200490228 |
0.344 |
|
| 2003 |
Giovannoni G, Polman CH, Petkau J, Thompson A, Dahlke F, Kappos L. Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b [4] (multiple letters) Neurology. 61: 1025. PMID 14557596 DOI: 10.1212/01.Wnl.0000082164.47224.79 |
0.457 |
|
| 2003 |
Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A, Hern J, Coleman R, Soelberg Srensen P, Hartung HP, Fredrikson S, Selmaj K, Pelletier J, ... ... Petkau J, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: A double-blind randomized study Multiple Sclerosis. 9: 342-348. PMID 12926838 DOI: 10.1191/1352458503ms923oa |
0.339 |
|
| 2003 |
Polman CH, Kappos L, Petkau J, Thompson A. Neutralising antibodies to interferon β during the treatment of multiple sclerosis [6] Journal of Neurology Neurosurgery and Psychiatry. 74: 1162. PMID 12876268 DOI: 10.1136/Jnnp.74.8.1162 |
0.373 |
|
| 1999 |
Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain : a Journal of Neurology. 122: 871-82. PMID 10355672 DOI: 10.1093/Brain/122.5.871 |
0.421 |
|
| 1999 |
Paszner B, Petkau J, Oger J. Neutralising antibodies to interferon-β in the treatment of multiple sclerosis: Cause for concern? Cns Drugs. 11: 225-243. DOI: 10.2165/00023210-199911030-00006 |
0.362 |
|
| 1999 |
Bajorski P, Petkau J. Nonparametric Two-Sample Comparisons of Changes on Ordinal Responses Journal of the American Statistical Association. 94: 970-978. DOI: 10.1080/01621459.1999.10474201 |
0.311 |
|
| 1998 |
Petkau J. Statistical methods for evaluating multiple sclerosis therapies Seminars in Neurology. 18: 351-375. PMID 9817539 DOI: 10.1055/S-2008-1040886 |
0.368 |
|
| 1997 |
Petkau J, White R. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis Multiple Sclerosis. 3: 402. PMID 9493643 DOI: 10.1177/135245859700300610 |
0.376 |
|
| 1997 |
D'yachkova Y, Petkau J, White R. Longitudinal analyses for magnetic resonance imaging outcomes in multiple sclerosis clinical trials Journal of Biopharmaceutical Statistics. 7: 501-531. PMID 9358326 |
0.326 |
|
| 1997 |
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force Annals of Neurology. 42: 379-382. PMID 9307263 DOI: 10.1002/Ana.410420318 |
0.34 |
|
| 1996 |
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, et al. Clinical outcomes assessment in multiple sclerosis Annals of Neurology. 40: 469-479. PMID 8797541 DOI: 10.1002/Ana.410400321 |
0.355 |
|
| Show low-probability matches. |